EUVIMEDEUVIMED entdecken
Crossref

Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy

Shunli Yu, Ruhe Zhang, Zhaoxiang Xie, Zhi Xiong, Shirong Peng, Bingheng Li, Ruilin Zhuang, Jun Wu iD, Hai Huang

ACS Biomaterials Science & Engineering · 2024

DOI: 10.1021/acsbiomaterials.4c00345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2024. Verfasst von Shunli Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China. Hauptthemen laut MEDLINE: Sorafenib, Prostatic Neoplasms, Nanoparticles, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Guangdong Provincial Department of Science and Technology, Sun Yat-sen University, Key Technologies Research and Development Program of Guangzhou Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) with a high incidence worldwide is a serious threat to men's health. Despite the continuous development of treatment strategies for PCa in recent years, the long-term prognosis of patients is still poor. Hence, the discovery and development of novel, secure, and efficient therapeutic approaches hold significant clinical significance. Although sorafenib (SOR) displays potential as a therapeutic option for PCa, its clinical efficacy is hindered by drug resistance, limited water solubility, and rapid metabolism. Therefore, we proposed to prepare nanoparticles (named SOR@8P4 NPs) utilizing the phenylalanine-based poly(ester amide) polymer (8P4) as the drug carrier to enhance the solubility and drug stability of SOR and improve the therapeutic targeting and bioavailability. SOR@8P4 NPs had high stability and showed acid-responsive drug release at the acidic tumor microenvironment. Additionally, SOR@8P4 NPs demonstrated more remarkable anticancer, antimetastatic, and antiproliferative abilities in vitro, compared with those of free drugs. SOR@8P4 NPs showed high tumor targeting and significantly inhibited tumor growth in vivo. In summary, the drug delivery system of SOR@8P4 NPs provides new ideas for the clinical treatment of PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibProstatic NeoplasmsNanoparticlesAntineoplastic AgentsMaleHumansAnimalsCell Line, TumorPolyestersMiceDrug CarriersAmidesDrug LiberationCell ProliferationMice, NudeMice, Inbred BALB C

Stichwörter der Autor:innen

drug deliverynanoparticlespoly(ester amide)prostate cancersorafenib

Substanzen

SorafenibAntineoplastic AgentsPolyestersDrug CarriersAmides

Autor:innen und Institutionen

  • Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
  • Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518107, China.
  • Bioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou 511400, China.
  • Division of Life Science, The Hong Kong University of Science and Technology, Hong Kong 999077, China.
  • Department of Urology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan 511518, Guangdong, China.

ORCID-Profile: Jun Wu

Förderung

  • Guangdong Provincial Department of Science and Technology
  • Sun Yat-sen University
  • Key Technologies Research and Development Program of Guangzhou Municipality
  • Guangzhou Medical University
  • Bethune Charitable Foundation
  • National Key Research and Development Program of China
  • Special Project for Research and Development in Key areas of Guangdong Province
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Yu, S., Zhang, R., Xie, Z., Xiong, Z., Peng, S., Li, B., Zhuang, R., Wu, J., & Huang, H. (2024). Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.4c00345

Vancouver

Yu S, Zhang R, Xie Z, Xiong Z, Peng S, Li B, et al. Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy. ACS Biomaterials Science & Engineering. 2024. doi:10.1021/acsbiomaterials.4c00345

BibTeX
@article{Yu2024,
  author = {Yu, Shunli and Zhang, Ruhe and Xie, Zhaoxiang and Xiong, Zhi and Peng, Shirong and Li, Bingheng and Zhuang, Ruilin and Wu, Jun and Huang, Hai},
  title = {Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy},
  journal = {ACS Biomaterials Science & Engineering},
  year = {2024},
  doi = {10.1021/acsbiomaterials.4c00345}
}
Kostenlos starten →